Aloxi injection is used in adults to help prevent the nausea and vomiting due to chemotherapy.
According to a statement issued by the Swiss drug maker, Aloxi is currently distributed by Helsinn Healthcare's marketing partner, Eisai Inc in the USA.
"As a result of the settlement, Dr Reddy's Laboratories Inc will be permitted to market a 505(j) generic version of Aloxi in the United States on September 30, 2018 or earlier under certain circumstances. The terms of the settlement agreement are otherwise confidential," the statement said.
Helsinn had earlier entered into similar agreement with Sandoz Inc.
Shares of Dr Reddy's were trading at Rs 4,178.40 apiece, down 0.29 per cent on BSE.